Colinz Lab Peer Comparison

BSE: 531210

₹70.30

₹-3.70 (-5.00%)

As on 31-Aug-2026 13:45IST

Market cap

₹18 Cr

Revenue (TTM)

₹6 Cr

P/E Ratio

6.3

P/B Ratio

1.4

Div. Yield

0 %

Edit

	Colinz Lab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	18	30,822	30,264	28,531	26,608
Revenue (₹ Cr)	6	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	2.80	414.00	288.22	-371.81	387.35
Net Margin (%)	44.08	11.23	14.79	-3.93	26.01
RoE (%)	5.10	8.38	29.77	-3.85	25.18
Price to Earnings	6.34	75.36	105.01	--	68.89
Price-To-Book	1.42	6.12	22.55	3.56	15.39

Income Statement (₹ Cr)

	Colinz Lab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	5.81	3,564.00	1,935.80	9,205.28	1,461.80
Total Income	6.34	3,686.00	1,948.58	9,449.59	1,489.25
Total Expenditure	5.48	2,792.00	1,485.56	8,195.15	919.25
EBITDA	0.33	772.00	450.24	1,010.13	542.56
Depreciation	0.16	226.00	50.83	857.51	37.68
EBIT	0.18	546.00	399.41	152.62	504.88
Interest	0.04	217.00	40.84	342.73	3.77
Other Income	0.53	122.00	12.78	244.31	27.45
Exceptional Items	2.76	12.00	0.00	-216.88	0.00
Profit before Tax	3.43	463.00	371.35	-162.68	528.56
Provision for Tax	0.63	49.00	83.14	209.13	141.21
Profit after Tax	2.80	414.00	288.22	-371.81	387.35

	Colinz Lab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	10.04	4,940.00	1,288.82	8,162.62	1,653.56
Minority Interest	0.00	-5.00	0.00	0.00	-1.13
Non-Current Liabilities	0.17	1,712.00	202.03	5,044.14	42.40
Current Liabilities	2.57	1,622.00	835.87	4,758.28	230.82
Total Liabilities	11.82	8,100.00	1,451.43	15,513.53	1,549.26

	Colinz Lab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	2.65	5,343.00	519.60	10,211.52	1,026.85
Current Assets	10.08	2,606.00	1,681.81	7,191.66	881.27
Total Assets	11.82	8,100.00	1,451.43	15,513.53	1,549.26
Total Debt*	0.64	1,859.00	393.17	4,720.27	8.18
Net Current Assets	7.51	984.00	845.94	2,433.38	650.46
Contingent Liabilities	--	770.26	12.25	99.76	15.38

	Colinz Lab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	-1.45	-22.00	159.18	892.30	118.34
Cash Flow from Investing Activities	-0.23	-783.00	-64.81	-477.46	-223.94
Cash from Financing Activities	0.24	409.00	-39.81	-440.83	261.12
Net Cash Inflow / Outflow	-1.45	-396.00	54.56	-25.99	155.52

	Colinz Lab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	6.74	4.07	26.97	6.61	20.14
ROE (%)	5.10	8.38	29.77	-3.85	25.18
ROA (%)	22.73	4.94	24.77	-2.21	21.93
EBIT Margin (%)	3.06	15.32	20.63	1.66	34.54
Net Margin (%)	44.08	11.23	14.79	-3.93	26.01
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Colinz Lab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	-8.43	18.37	46.65	0.78	40.90
EBIT Growth (%)	-46.71	252.26	62.13	-70.53	124.50
Net Profit Growth (%)	484.73	377.85	89.49	-1,383.43	104.15
EPS Growth (%)	6.32	1,001.33	78.60	-484.84	42.32
Book Value Growth (%)	5.87	29.77	42.49	2.28	94.96

	Colinz Lab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	36.68	80.56	102.12	-93.01	69.57
Price / Book Value	1.50	6.38	22.27	3.64	15.55
Dividend Yield (%)	0.00	0.00	0.08	0.00	0.08
EV/EBITDA	41.11	43.48	66.20	32.91	49.08
Market Cap (₹ Cr)	18.25	23,064.69	0.00	29,731.27	19,988.69

	Colinz Lab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.00	0.31	0.11	0.53	0.01
Short term debt to equity ratio	0.07	0.11	0.54	0.12	0.02
Current Ratio	3.93	1.61	2.01	1.51	3.82
Quick Ratio	3.65	1.06	1.14	0.87	2.82
Interest Coverage	82.64	3.13	10.09	0.53	141.16

	Colinz Lab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	14.37	16.50	26.28	23.44	24.80
Asset Turnover	0.47	0.43	1.66	0.55	0.83
Receivable days	42.50	60.36	47.59	77.05	90.06
Inventory Days	45.51	64.42	62.58	77.13	61.02
Payable days	99.60	218.94	228.78	173.49	96.06
Cash Conversion Cycle	-11.59	-94.15	-118.62	-19.30	55.02

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.